Jazz Pharmaceuticals PLC (JAZZ.O) Key Developments | Reuters.com
Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.O)

JAZZ.O on Nasdaq

136.35USD
10:47am EDT
Change (% chg)

$3.74 (+2.82%)
Prev Close
$132.61
Open
$134.95
Day's High
$137.29
Day's Low
$133.38
Volume
221,435
Avg. Vol
795,582
52-wk High
$194.73
52-wk Low
$108.50

Latest Key Developments (Source: Significant Developments)

S&P-Jazz Pharmaceuticals Plc ratings affirmed on Celator acquisition plan outlook stable
Tuesday, 31 May 2016 06:04pm EDT 

S&P : Stable rating outlook reflects expectation that leverage will remain comfortably below 3x . Jazz pharmaceuticals plc ratings affirmed on Celator acquisition plan; outlook stable . Do not expect Celator to contribute meaningful sales and cash flows until 2018 Source (http://bit.ly/1TIwM22) Further company coverage: [JAZZ.O,CPXX.O] (Bengaluru Newsroom) (((+91 80 6749-1130; within U.S. +1 646 223 8780);)).  Full Article

Jazz Pharmaceuticals Q1 gaap earnings per share $1.19
Tuesday, 10 May 2016 05:00pm EDT 

Jazz Pharmaceuticals Plc : Sees 2016 revenues $1,490 million -$1,550 million . Sees 2016 gaap net income per diluted share $6.76-$7.41 . Sees 2016 non-gaap adjusted net income per diluted share $11.10-$11.50 . Sees 2016 total net product sales $1,482 million -$1,542 million . Sees 2016 adjusted gross margin 93% . Fy2016 earnings per share view $11.14, revenue view $1.53 billion -- Thomson Reuters I/B/E/S . Jazz pharmaceuticals announces first quarter 2016 financial results . Q1 adjusted earnings per share $2.26 . Q1 gaap earnings per share $1.19 . Q1 earnings per share view $2.31 -- Thomson Reuters I/B/E/S .Q1 revenue $336 million versus i/b/e/s view $338.9 million.  Full Article

Jazz Pharmaceuticals PLC announces FDA approval of Defitelio for treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation
Wednesday, 30 Mar 2016 02:32pm EDT 

Jazz Pharmaceuticals PLC:Says FDA granted marketing approval for Defitelio for treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome, with renal or pulmonary dysfunction following HSCT.  Full Article

Jazz Pharmaceuticals PLC gives FY 2016 guidance
Tuesday, 23 Feb 2016 04:05pm EST 

Jazz Pharmaceuticals PLC:Sees FY 2016 Revenues $1,490-$1,550 million.Sees FY 2016 Total net product sales $1,482-$1,542 million.Sees FY 2016 GAAP net income per diluted share $6.76-$7.41.Sees FY 2016 Non-GAAP adjusted net income per diluted share $10.90-$11.30.  Full Article

Jazz Pharmaceuticals PLC narrows FY 2015 guidance
Monday, 9 Nov 2015 04:05pm EST 

Jazz Pharmaceuticals PLC:Expects FY 2015 revenues of $1.320-$1.340 billion.Expects FY 2015 GAAP net income per diluted share of $5.42-$5.63.Expects FY 2015 Non-GAAP adjusted net income per diluted share of $9.45-$9.60.FY 2015 revenue of $1.35 billion and EPS of $9.67 - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC announces U.S. FDA acceptance for filing with priority review of nda for defibrotide for hepatic veno-occlusive disease
Wednesday, 30 Sep 2015 08:30am EDT 

Jazz Pharmaceuticals PLC:Announces U.S. FDA acceptance for filing with priority review of nda for defibrotide for hepatic veno-occlusive disease.Says FDA review of the nda is expected to be completed by March 31, 2016.  Full Article

Jazz Pharmaceuticals PLC reaffirms FY 2015 guidance
Wednesday, 5 Aug 2015 04:05pm EDT 

Jazz Pharmaceuticals PLC:Reaffirms FY 2015 guidance.Expects FY 2015 revenues of $1.310-$1.370 billion.Expects FY 2015 GAAP net income per diluted share of $5.17-$5.70.Expects FY 2015 Non-GAAP adjusted net income per diluted share of $9.45-$9.75.FY 2015 revenue of $1.36 billion and EPS of $9.67 - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC reaffirms FY 2015 guidance
Thursday, 7 May 2015 04:05pm EDT 

Jazz Pharmaceuticals PLC:Reaffirms FY 2015 guidance.Expects FY 2015 revenues of $1.310-$1.370 billion.Expects FY 2015 GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share of $5.17-$5.70.Expects FY 2015 Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share of $9.45-$9.75.FY 2015 revenue of $1.36 billion - Thomson Reuters I/B/E/S.  Full Article

Jazz Pharmaceuticals PLC completes sale of certain products that company originally acquired as part of company’s acquisition of EUSA Pharma Inc and business related thereto - Form 8-K
Monday, 23 Mar 2015 09:11am EDT 

Jazz Pharmaceuticals PLC:As previously disclosed, company entered into an agreement in the fourth quarter of 2014 to sell certain products that company originally acquired as part of Company’s acquisition of EUSA Pharma Inc. and business related thereto to Essex Bidco Limited, a company controlled by Essex Woodlands.On March 20, the Company completed the sale of the Disposed Business pursuant to the Sale Agreement.Pursuant to the Sale Agreement, the purchase price for the Disposed Business was $34 mln, subject to certain adjustments.As of the closing, the Company was entitled to receive about $33 mln in cash after purchase price adjustments were made prior to the closing.Purchase price is subject to potential further adjustments post-closing.Products in the Disposed Business sold to Essex included Caphosol (supersaturated calcium phosphate rinse), Collatamp (lyophilized collagen implant impregnated with the aminoglycoside antibiotic gentamicin), Fomepizole (fomepizole), Xenazine (tetrabenazine) and Custodiol.  Full Article

Jazz Pharmaceuticals PLC gives FY 2015 guidance below analysts' estimates
Tuesday, 24 Feb 2015 04:05pm EST 

Jazz Pharmaceuticals PLC:Expects FY 2015 revenues of $1.310-$1.370 billion.Expects FY 2015 GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share of $5.17-$5.70.Expects FY 2015 Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share of $9.45-$9.75.FY 2015 revenue of $1.40 billion and EPS of $10.11 - Thomson Reuters I/B/E/S.  Full Article

BRIEF-Jazz Pharma presents data from study for treatment for excessive sleepiness

* Presents new data from a human abuse liability study for JZP-110, an investigational treatment for excessive sleepiness in patients with narcolepsy or with OBSTR